iOnctura is developing next generation, best-in-class molecules with dual therapeutic potential in cancer and fibrotic indications. iOnctura’s programs harness immune-mediated and direct anti-tumour activity, to deliver superior clinical efficacy in oncology.
In addition to expected monotherapeutic benefit, the immunological nature of the targets in our portfolio mean that clinical potential in oncology may be maximised by selecting rational combination strategies for each molecule, including combinations within the pipeline.
The cellular and microenvironmental processes in chronic fibrosis and cancer are the same; the same cell types, soluble and matrix elements control chronic fibrosis and cancer development / progression. iOnctura is building on this link to address cancer associated fibrosis which hinders therapeutic response to treatments including immunotherapies, as well as exploring efficacy in a range of fibrotic indications.
iOnctura’s most advanced program, IOA-244, is a next generation PI3Kδ inhibitor with a unique chemical structure, exquisite selectivity, excellent drug-like properties and potentially a best-in-class safety profile. It is being developed as a novel, targeted therapy for solid tumours that are burdened with an immune-suppressive tumour microenvironment. First-in-human studies in patients are expected to start in Q1 2019. Preclinical exploration of IOA-244 as novel treatment for fibrotic indications is ongoing.
The binding mode of IOA-244 is unique as well as its non-ATP competitive nature of binding. We expect this to drive the exquisite selectiveness for PI3Kδ but also target cells that have a high metabolic activity e.g. cancer cells and immune cells.
iOnctura’s second program, IOA-289, is a novel autotaxin (ATX) inhibitor with a superior potency and in vitro safety profile compared to existing ATX inhibitors. It is being developed as a first-in-class targeted therapy for solid tumours that over express ATX and are subject to lipid mediated immune suppression as well as a best-in-class therapy for Idiopathic Pulmonary Fibrosis (IPF).
IOA-289 has already demonstrated preclinical proof-of-concept in tumour models and is expected to enter the clinic in early 2020.
iOnctura also has an early pipeline of antibody candidates.